Literature DB >> 33842223

Reinventing the displacement left ventricular assist device in the continuous-flow era: TORVAD, the first toroidal-flow left ventricular assist device.

Carlo R Bartoli1, Jeffrey R Gohean2, Richard W Smalling2,3.   

Abstract

Year:  2021        PMID： 33842223      PMCID： PMC8033259          DOI： 10.21037/acs-2020-cfmcs-19

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  9 in total

1.  Do patients with a continuous-flow left ventricular assist device benefit from induced-pulsatility or are we just spinning our wheels?

Authors:  Carlo R Bartoli; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2015-07-20       Impact factor: 5.209

2.  Clinical and In Vitro Evidence That Subclinical Hemolysis Contributes to LVAD Thrombosis.

Authors:  Carlo R Bartoli; David Zhang; Jooeun Kang; Samson Hennessy-Strahs; David Restle; Jessica Howard; Gretchen Redline; Christian Bermudez; Pavan Atluri; Michael A Acker
Journal:  Ann Thorac Surg       Date:  2017-09-21       Impact factor: 4.330

Review 3.  Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.

Authors:  James K Kirklin; Francis D Pagani; Robert L Kormos; Lynne W Stevenson; Elizabeth D Blume; Susan L Myers; Marissa A Miller; J Timothy Baldwin; James B Young; David C Naftel
Journal:  J Heart Lung Transplant       Date:  2017-07-15       Impact factor: 10.247

4.  Preload Sensitivity with TORVAD Counterpulse Support Prevents Suction and Overpumping.

Authors:  Jeffrey R Gohean; Erik R Larson; Raul G Longoria; Mark Kurusz; Richard W Smalling
Journal:  Cardiovasc Eng Technol       Date:  2019-06-11       Impact factor: 2.495

5.  Improved left ventricular unloading and circulatory support with synchronized pulsatile left ventricular assistance compared with continuous-flow left ventricular assistance in an acute porcine left ventricular failure model.

Authors:  George V Letsou; Thomas D Pate; Jeffrey R Gohean; Mark Kurusz; Raul G Longoria; Larry Kaiser; Richard W Smalling
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05-23       Impact factor: 5.209

6.  Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.

Authors:  Carlo R Bartoli; David J Restle; David M Zhang; Michael A Acker; Pavan Atluri
Journal:  J Thorac Cardiovasc Surg       Date:  2014-09-18       Impact factor: 5.209

7.  Scaling the Low-Shear Pulsatile TORVAD for Pediatric Heart Failure.

Authors:  Jeffrey R Gohean; Erik R Larson; Brian H Hsi; Mark Kurusz; Richard W Smalling; Raul G Longoria
Journal:  ASAIO J       Date:  2017 Mar/Apr       Impact factor: 2.872

8.  Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.

Authors:  Carlo R Bartoli; David M Zhang; Samson Hennessy-Strahs; Jooeun Kang; David J Restle; Christian Bermudez; Pavan Atluri; Michael A Acker
Journal:  Circ Heart Fail       Date:  2018-09       Impact factor: 8.790

9.  A Novel Toroidal-Flow Left Ventricular Assist Device Minimizes Blood Trauma: Implications of Improved Ventricular Assist Device Hemocompatibility.

Authors:  Carlo R Bartoli; Samson Hennessy-Strahs; Jeff Gohean; Maryann Villeda; Erik Larson; Raul Longoria; Mark Kurusz; Michael A Acker; Richard Smalling
Journal:  Ann Thorac Surg       Date:  2018-12-23       Impact factor: 5.102
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.